Browsing by Author SHEK, HP

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 2 to 9 of 9 < previous 
TitleAuthor(s)Issue DateViews
 
Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma
Journal:International Journal of Hepatology
Shek, HPFatima, SLee, NPY
2012
31
 
miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma
Journal:PLoS ONE
Liu, MLXu, ZShek, HPWong, KFLee, NPYPoon, RTPChen, JLuk, JMC
2014
47
 
Oncofetal Molecules as Biomarkers and Drug Targets for Hepatic Cancer
Book:New Advances on Disease Biomarkers and Molecular Targets in Biomedicine
Shek, HPLai, TCWFatima, SLee, NPY
2013
62
 
Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2
Journal:Digestive Diseases and Sciences
TSANG, FHAu, CHVLU, WSHEK, HPLIU, MLLuk, JMCFan, STPoon, RTPLee, NPY
2014
52
 
Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma
Journal:Cellular Oncology
SHEK, HPLuo, RLam, BYHSung, WKLam, TWLuk, JMCLeung, MSChan, KTWang, KSHChan, CMGPoon, RTPLee, NPY
2017
95
 
Targeting Serine Peptidase Inhibitor, Kazal Type 1 (SPINK1) as a Potential Treatment for Hepatocellular Carcinoma
Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2011
Shek, HPLuk, JMCLee, NPY
2011
131
 
The role of serine peptidase inhibitor, Kazal type I (SPINK1) in hepatocellular carcinoma
Proceeding/Conference:Cancer Omics
Shek, HPLuk, JMCKwong, ALee, NPY
2010
 
Tumorigenic properties of serine peptidase inhibitor, Kazal type 1 (SPINK1) in hepatocellular carcinoma
Proceeding/Conference:Hong Kong International Cancer Congress, HKICC 2011
Shek, HPLee, NPY
2011
123
Showing results 2 to 9 of 9 < previous